TY - CHAP M1 - Book, Section TI - Fibrinolysis and Thrombolysis A1 - Hajjar, Katherine A. A1 - Ruan, Jia A2 - Kaushansky, Kenneth A2 - Lichtman, Marshall A. A2 - Prchal, Josef T. A2 - Levi, Marcel M. A2 - Press, Oliver W. A2 - Burns, Linda J. A2 - Caligiuri, Michael Y1 - 2015 N1 - T2 - Williams Hematology, 9e AB - SUMMARYImproved understanding of the molecular mechanisms of fibrinolysis has led to major advances in fibrinolytic and antifibrinolytic therapy. Characterization of the genes for all the major fibrinolytic proteins has revealed the structure of the relevant serine proteases, their inhibitors, and their receptors. The development of genetically engineered animals deficient in one or more fibrinolytic protein(s) has revealed both expected and unexpected functions. In addition, we now have a catalog of acquired and inherited disorders reflective of either fibrinolytic deficiency with thrombosis or fibrinolytic excess with hemorrhage. These advances have led to development of more effective and safer protocols for both pro- and antifibrinolytic therapy in a variety of circumstances. SN - PB - McGraw-Hill Education CY - New York, NY Y2 - 2024/03/29 UR - hemonc.mhmedical.com/content.aspx?aid=1121105501 ER -